Yumanity Therapeutics (FRA:8IY) Change In Receivables : €4.54 Mil (TTM As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Yumanity Therapeutics Change In Receivables?

Yumanity Therapeutics's change in receivables for the quarter that ended in Sep. 2022 was €0.00 Mil. It means Yumanity Therapeutics's Accounts Receivable stayed the same from Jun. 2022 to Sep. 2022 .

Yumanity Therapeutics's change in receivables for the fiscal year that ended in Dec. 2021 was €-4.43 Mil. It means Yumanity Therapeutics's Accounts Receivable increased by €4.43 Mil from Dec. 2020 to Dec. 2021 .

Yumanity Therapeutics's Accounts Receivable for the quarter that ended in Sep. 2022 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Yumanity Therapeutics's Days Sales Outstanding for the three months ended in Sep. 2022 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Yumanity Therapeutics's liquidation value for the three months ended in Sep. 2022 was €4.36 Mil.

Yumanity Therapeutics Change In Receivables Historical Data

The historical data trend for Yumanity Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yumanity Therapeutics Change In Receivables Chart

Yumanity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Change In Receivables

-4.43

Yumanity Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Change In Receivables	Get a 7-Day Free Trial							-	-	4.54	-	-

Yumanity Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.54 Mil.

Yumanity Therapeutics (FRA:8IY) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Yumanity Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2022 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	1.416	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, Yumanity Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Yumanity Therapeutics's liquidation value for the quarter that ended in Sep. 2022 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	8.5	-	4.144	+	0.75 * 0	+	0.5 * 0
=	4.36

Yumanity Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Yumanity Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Yumanity Therapeutics (FRA:8IY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yumanity Therapeutics Inc (FRA:8IY) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

40 Guest Street, Suite 4410, Boston, MA, USA, 02135

Website

https://www.yumanity.com

Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.

Yumanity Therapeutics (FRA:8IY) Headlines

No Headlines